assessment of recurrent brain tumor

24
Assessment of Recurrent Brain Tumor by 18 F-FDG PET and SPECT Using 201 Tl, 99m Tc-MIBI, and 99m Tc-ECD

Upload: fondas-vakalis

Post on 27-Jul-2015

1.617 views

Category:

Health & Medicine


1 download

TRANSCRIPT

Page 1: Assessment Of  Recurrent  Brain  Tumor

Assessment of Recurrent Brain Tumor by 18F-FDG PET and SPECT Using 201Tl, 99mTc-MIBI, and 99mTc-ECD

Page 2: Assessment Of  Recurrent  Brain  Tumor

Background

To differentiate between recurrent brain tumor and radiation necrosis is a difficult diagnostic problem.Neither the symptoms nor the conventional radiographic findings clearly distinguish tumor from necrosis.Sampling error in biopsying such lesions may lead to misdiagnosis.

Page 3: Assessment Of  Recurrent  Brain  Tumor

Background201Tl SPECT

changes in blood flow, BBB breakdown, transmembrane transport into viable tumor cell proportional to Na/K ATPase

99mTc-MIBI SPECT electronic potential across the cell membrane, blood flow,

metabolic activity of the cell18F-FDG PET

Increased expression of glucose transporter molecules, Increased hexokinase, reduced glucose-6-phosphotase

In vitro studies: Vialble cancer cell number are best correlated with FDG uptake in brain tumor.

Page 4: Assessment Of  Recurrent  Brain  Tumor

Background

We reported a case of hypothalamus tumor who had been treated with radiotherapy. Recurrent lesion was suspected on MR images.18F-FDG PET, SPECT using 201Tl, 99mTc-MIBI, and 99mTc-ECD were used together to define the nature of the lesion and to guide treatment planning.

Page 5: Assessment Of  Recurrent  Brain  Tumor

Case presentation

Clinical history 49 y/o female 89-4: Left hypothalamus tumor found at KHVGH.

MRI: T1W1:homogeneous, hypointensity, enhancement(-). Biopsy can not be performed due to the deep location.

89-6: arranged R/T presumed low-grade glioma. (61.2 Gy/34 fractions)

91-7: Right side headache. MRI found a new lesion in right frontal and corpus callosum region, measuring about 2 cm.

Page 6: Assessment Of  Recurrent  Brain  Tumor

TIWI

hypointensity with heterogenous enhancement

T2WI

edema around the lesion

Page 7: Assessment Of  Recurrent  Brain  Tumor

Case presentation18F-FDG PET at VGH, Taipei Head and neck and brain imaging from head to sh

oulder was performed at 45mins after intravenous injection of 11.64mCi of 18F-FDG.

Siemens EXACT HR+ scanner Fasting for 6 hrs was required proor to the scannin

g. Imaging was reconstructed iteratively with attenuat

ion correction.

Page 8: Assessment Of  Recurrent  Brain  Tumor

Case presentationSPECT 201Tl: 5mCi, 99mTc-MIBI: 30mCi

acquire images 15 mins after injection. 60 projections, 60s per view, 128x128 matrix Semi-quantitative analysis:

The L/N ratio: average counts for the ROI in the lesion to its mirror image in normal brain tissue.

99mTc-ECD: 20mCi Acquire images 30 mins after injection. 60 projections, 60s per view, 128x128 matrix

(triple-head gamma camera, fanbeam collimator)

Page 9: Assessment Of  Recurrent  Brain  Tumor

FDG-PETThallium

MIBI ECD

Page 10: Assessment Of  Recurrent  Brain  Tumor

Case presentationThe L/N ratio: Tl: 2.71, MIBI: 7.94

The imaging results of 18F-FDG PET, 201 Tl and 99mTc-MIBI SPECT are indicative of viable tumor.

The patient went on 2nd R/T in 92-4. (50.4Gy)

Follow-up exams with MRI, 201 Tl and 99mTc-MIBI SPECT were performed in 92-8.

Page 11: Assessment Of  Recurrent  Brain  Tumor

89-4

92-8

Pre-R/T91-10

1st R/T

2ndR/T

Page 12: Assessment Of  Recurrent  Brain  Tumor

91-10 post 1st R/T 92-8 post 2nd R/T

Thallium

MIBI

MRI (T1WI)

Page 13: Assessment Of  Recurrent  Brain  Tumor

92-8 post 2nd R/T

T1WI C(+) Thallium

A new lesion in left mesial temporal.

Page 14: Assessment Of  Recurrent  Brain  Tumor

Summary89-4: left hypothalamus tumor89-6: 1st radiotherapy 91-10: right frontal new lesion on MRI recurrence or radiation necrosis? 18F-FDG PET, SPECT of 201Tl, 99mTc-MIBI were compatible with r

ecurrence.

92-4: 2nd radiotherapy 92-8: follow-up clinical symptom deterioration right frontal lesion progression: T1WI(+), Tl(+), MIBI(+). a new lesion in left mesial temporal: T1WI(+), Tl(+), MIBI(-).

Page 15: Assessment Of  Recurrent  Brain  Tumor

Discussion

Page 16: Assessment Of  Recurrent  Brain  Tumor

Recurrent tumor vs radiation necrosis

Similar symptomsOverlapping onset time radiation necrosis: within 1 to 2 years after

treatment is complete

MRI: indistinguishable contrast enhancement central necrosis variable edema and mass effect radiation necrosis: sometimes distant from the

tumor site

Page 17: Assessment Of  Recurrent  Brain  Tumor

Recurrent tumor vs radiation necrosis

201Tl SPECT Yoshii et al. have shown the superiority of Tl-201 SPECT ov

er MRI. (Eur J Nucl Med 1993,20:39) Dierckx et al.

90 patients for diagnosing brain tumor Sensitivity: 71.7%, specificity: 80.9% (Eur J Nucl Med 1994,21:621)

99mTc-MIBI SPECT Yamamoto et al. compared MIBI with Tl in 21 patients and fo

und same accuracy (90%). (Nucl Med commun 2002,23:1183) O’Tuama et al. compared MIBI and Tl in 19 children with brai

n tumors. sensitivity: 67% for both specifisity: 91% for Tl, 100% for MIBI (J Nucl Med 1993,34:1045)

Page 18: Assessment Of  Recurrent  Brain  Tumor

Recurrent tumor vs radiation necrosis

18F-FDG PET Int J Cancer 2001,96:191: 47 patients, recu

rrence after R/T Sensitivity: 75%, specificity: 81%

In our patient, MRI can not reliably distinguish recurrence from necrosis. FDG-PET, Tl and MIBI SPECT showed increased uptake.

Page 19: Assessment Of  Recurrent  Brain  Tumor

Recurrent tumor vs radiation necrosis

Uptake ratio in Tl and MIBI SPECT: Kosuda et al. (Tl, L/N ratio)

Recurrence: 1.7 to 12.6. All but one >2.5 Necrosis: always <=2.5 (Ann Nucl Med 1993,7:25

7)

Yamamoto et al. (L/N ratio) Cutoff value: Tl:2.40, MIBI: 5.89 accuracy: 90% (Nucl Med commun 2002,23:118

3)

Cutoff of Tl among previous reports: 1.5~2.5

In our patient, L/N ratio: Tl: 2.71, MIBI: 7.94, indicative of viable tumor.

Page 20: Assessment Of  Recurrent  Brain  Tumor

201Tl SPECT v.s. 18F-FDG PETBlack et al. equally good correlation with glioma grade sensitivity for recurrence: Tl:100%, PET:90.9%.

Kahn D et al.(19 pts, recurrence): ComparableOne disappointing report for PET (Am J Neuroradiol 1998)

86% and 22% (white matter); 73% and 56% (gray matter)

Difficulty in detection Low-grade tumor have metabolic activity resembling white m

atter. High-grade tumor have metabolic activity resembling gray m

atter.

Page 21: Assessment Of  Recurrent  Brain  Tumor

201Tl SPECT v.s. 18F-FDG PET

In our patient, Tl and MIBI SPECT offered equal information as FDG-PET.

Considering cost, availability, simplicity, ease of interpretation, SPECT should be considered in such cases.

Page 22: Assessment Of  Recurrent  Brain  Tumor

201Tl v.s. 99mTc-MIBIComparable in previous reportsIn our patient, the new left mesial temporal lesion is Tl(+), MIBI(-). L/N ratio of Tl: 2.67.B. BAGNI et al.: Lesions are more easily detected in frontal-parietal

area than in temporal lobes. (Nucl Med Commun 1995,16:258)

A false-negative MIBI SPECT was reported by Goethals I et al. Suggest other mechanism involved in MIBI accum

ulation. (Clin Nucl Med 2003,28:299)

Page 23: Assessment Of  Recurrent  Brain  Tumor

Conclusion

201Tl and 99mTc-MIBI SPECT, 18F-FDG PET provide useful information when encountering a contrast-enhancing mass on MRI in patients with previous radiation therapy for brain tumors.201Tl and 99mTc-MIBI SPECT provide equally useful information as 18F-FDG PET.

The discrepancy in the present case needs more study to survey.

Page 24: Assessment Of  Recurrent  Brain  Tumor

Thank you for your attention!